Key Considerations Before Investing in HIMS

By Susan Ramirez • Tuesday, August 26 10:12 • Permanent Link

Hims & Hers Health logged a 1.5% change during today's morning session, and is now trading at a price of $43.62 per share. The S&P 500 index moved 0.0%. HIMS's trading volume is 4,544,133 compared to the stock's average volume of 38,490,285.

Hims & Hers Health trades -11.8% away from its average analyst target price of $49.45 per share. The 11 analysts following the stock have set target prices ranging from $28.0 to $85.0, and on average have given Hims & Hers Health a rating of hold.

If you are considering an investment in HIMS, you'll want to know the following:

Hims & Hers Health's current price is 790.2% above its Graham number of $4.9, which implies that at its current valuation it does not offer a margin of safety
Hims & Hers Health has moved 189.7% over the last year, and the S&P 500 logged a change of 14.5%
Based on its trailing earnings per share of 0.79, Hims & Hers Health has a trailing 12 month Price to Earnings (P/E) ratio of 55.2 while the S&P 500 average is 29.3
HIMS has a forward P/E ratio of 94.8 based on its forward 12 month price to earnings (EPS) of $0.46 per share
Its Price to Book (P/B) ratio is 17.5 compared to its sector average of 3.19
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally.
Based in San Francisco, the company has 1,637 full time employees and a market cap of $9.86 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.